XOMAP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health...

Stats
Šios dienos apimtis	1.00
Vidutinė apimtis	1 406.00
Rinkos kapitalizacija	300.18M
EPS	$-0.480 ( 2023-09-29 )
Last Dividend	$0.539 ( 2023-10-04 )
Next Dividend	$0 ( N/A )
P/E	24.96
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Hughes Owen	Buy	275 000	Performance Stock Units
2023-10-03	Sitko Bradley	Buy	250	Common Stock
2023-10-02	Sitko Bradley	Buy	1 500	Common Stock
2023-10-02	Hughes Owen	Buy	1 000	Common Stock
2023-09-26	Hughes Owen	Buy	2 499	Common Stock

INSIDER POWER
100.00
Last 90 transactions
Buy: 3 445 824 \| Sell: 117 506

XOMA Corporation Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RNEM	0.944
IVAC	0.943
SCZ	0.939
RNDM	0.939
NECB	0.939
IDLB	0.938
ISDX	0.936
VYMI	0.935
KE	0.935
RFDI	0.935

10 Labiausiai neigiamai susiję koreliacijos
LYRA	-0.943
IMRX	-0.936
LYEL	-0.935
STRC	-0.935
NKTX	-0.933
NUWE	-0.932
GRNV	-0.931
SWVL	-0.931
ONCS	-0.93
GROM	-0.929

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

XOMA Corporation Finansinės ataskaitos

Annual	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2022
Pajamos:	$6.03M
Bruto pelnas:	$5.93M (98.39 %)
EPS:	$-1.500

FY	2021
Pajamos:	$38.16M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

XOMA Corporation Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.539 (N/A)	$0 (N/A)	$0.539 (N/A)	$1.078 (N/A)	$0 (N/A)	$0.539 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XOMA Corporation Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.719	2021-03-31
Last Dividend	$0.539	2023-10-04
Next Dividend	$0	N/A
Payout Date	2023-10-16
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$6.11	--
Avg. Dividend % Per Year	5.02%	--
Score	3.62	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-15)

$0.550 Estimate 20.00 %

Dividend Stability

0.53 Average

Dividend Score

3.62

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2021	$1.797	7.14%
2022	$2.16	8.31%
2023	$2.16	8.82%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-10.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.208	1.200	-6.93	-8.32	[0 - 0.3]
returnOnEquityTTM	-0.465	1.500	-6.28	-9.42	[0.1 - 1]
payoutRatioTTM	-0.112	-1.000	-1.123	1.123	[0 - 1]
currentRatioTTM	8.68	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.87	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.530	-1.500	1.171	-1.757	[0 - 0.6]
interestCoverageTTM	-130.17	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.582	2.00	-0.527	-1.055	[0 - 30]
freeCashFlowPerShareTTM	-2.86	2.00	-1.430	-2.86	[0 - 20]
debtEquityRatioTTM	1.399	-1.500	4.40	-6.61	[0 - 2.5]
grossProfitMarginTTM	0.811	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-5.80	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.146	1.000	-1.924	-1.924	[0.2 - 2]
assetTurnoverTTM	0.0203	0.800	-3.20	-2.56	[0.5 - 2]
Total Score				-1.689

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-6.08	1.000	-0.715	0	[1 - 100]
returnOnEquityTTM	-0.465	2.50	-4.04	-9.42	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.86	2.00	-0.953	-2.86	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.582	2.00	-0.527	-1.055	[0 - 30]
payoutRatioTTM	-0.112	1.500	-1.123	1.123	[0 - 1]
pegRatioTTM	-0.119	1.500	-4.13	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.82	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.16

XOMA Corporation

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.